AbbVie is set to buy Gilgamesh Pharmaceuticals’ lead candidate, GM-2505 (bretisilocin), in a deal worth up to $1.2bn. Here, we take a closer look at the acquisition, what it might tell us about big pharma’s interest in the field, and what it might mean for the broader crop of psychedelic drug developers…| Psychedelic Alpha
This morning, in a world-first move, Norwegian regulators approved national reimbursement for the off-label use of generic ketamine in treatment-resistant depression. Here, we break the news, dive deeper, and speak with insiders.| Psychedelic Alpha
Explore our interactive database of psychedelic patent activity in July 2025 via our Pα+ interface. Plus, we look at how a new patent family provides a look at Rivo Bio.| Psychedelic Alpha
This morning, Reunion Neuroscience posted positive topline results from its Phase 2 study of RE104, its 4-OH-DiPT prodrug, in postpartum depression (PPD). We spoke with Reunion leadership to dig deeper into safety and efficacy data, the trial’s design and protocol, as well as the company’s plans for future development of the candidate in PPD and beyond.| Psychedelic Alpha
One year after FDA’s rejection of Lykos Therapeutics’ MDMA-assisted therapy for PTSD application, insiders and observers reflect on what went wrong and what comes next. This in-depth, interview-led coverage explores the decisive factors behind the CRL, lessons learned, and the future of psychedelic drug development.| Psychedelic Alpha
Q2’25 Psychedelic Lobbying Update • Tabernanthalog Spurs Neuroplasticity via Alternative Pathway, Davis and Delix Researchers Find • UK Moves Toward Easing Schedule I Research Restrictions But Keeps Industry at Arm’s Length • “Shell Games” and Whistleblowers: MassGOP Goes on Offensive Against Psychedelics Campaigners • Aussie University Seeks Public Comments on MDMA Clinical Practice Guideline • and more..| Psychedelic Alpha
Psychedelic Alpha’s Charles Bliss speaks with Professor Celia Morgan, a leading ketamine researcher, about the promise of ketamine-assisted therapy for alcohol use disorder, rising concerns over recreational abuse, and her thoughts on proposals to reclassify the drug in the UK.| Psychedelic Alpha
AbbVie Eyes Billion-Dollar Gilgamesh Acquisition • What Is Kyrsten Sinema Selling? • Compass ‘Encouraged’ by Germany’s Psilocybin Compassionate Use Program • Psychedelics Industry’s Input on EMA’s Draft Depression Guideline • National Survey Reveals Psychedelics Use Again Rises in US • FDA Moves to Ban Kratom Compound 7-OH • Compass Talks Accelerated Approval on Q2’25 Earnings Call • atai All-In on Psychedelics Following RL-007 Flop • UK Government Publishes Life S...| Psychedelic Alpha
Here, we share Dr. Alaina Jaster’s observations from the inaugural Neurobiology of Psychedelics Gordon Research Conference, where leading scientists gathered to explore various realms of psychedelic…| Psychedelic Alpha
In a candid conversation with Psychedelic Alpha’s Josh Hardman, former U.S. Senator Kyrsten Sinema shares her case for ibogaine, sidesteps what she describes as ‘drama’, and lays out a strategy for…| Psychedelic Alpha
Australia’s largest private health insurer, Medibank, has launched a first-of-its-kind funding program for MDMA-assisted therapy for PTSD as part of its ‘innovative psychotherapy program’.| Psychedelic Alpha
